258 related articles for article (PubMed ID: 24849471)
1. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis.
Ford N; Mofenson L; Shubber Z; Calmy A; Andrieux-Meyer I; Vitoria M; Shaffer N; Renaud F
AIDS; 2014 Mar; 28 Suppl 2():S123-31. PubMed ID: 24849471
[TBL] [Abstract][Full Text] [Related]
2. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis.
Ford N; Calmy A; Mofenson L
AIDS; 2011 Nov; 25(18):2301-4. PubMed ID: 21918421
[TBL] [Abstract][Full Text] [Related]
3. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts.
Ford N; Mofenson L; Kranzer K; Medu L; Frigati L; Mills EJ; Calmy A
AIDS; 2010 Jun; 24(10):1461-70. PubMed ID: 20479637
[TBL] [Abstract][Full Text] [Related]
4. Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011.
Floridia M; Mastroiacovo P; Tamburrini E; Tibaldi C; Todros T; Crepaldi A; Sansone M; Fiscon M; Liuzzi G; Guerra B; Vimercati A; Vichi F; Vicini I; Pinnetti C; Marconi AM; Ravizza M;
BJOG; 2013 Nov; 120(12):1466-75. PubMed ID: 23721372
[TBL] [Abstract][Full Text] [Related]
5. Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs.
Veroniki AA; Antony J; Straus SE; Ashoor HM; Finkelstein Y; Khan PA; Ghassemi M; Blondal E; Ivory JD; Hutton B; Gough K; Hemmelgarn BR; Lillie E; Vafaei A; Tricco AC
PLoS One; 2018; 13(6):e0198447. PubMed ID: 29912896
[TBL] [Abstract][Full Text] [Related]
6. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants.
Williams PL; Crain MJ; Yildirim C; Hazra R; Van Dyke RB; Rich K; Read JS; Stuard E; Rathore M; Mendez HA; Watts DH;
JAMA Pediatr; 2015 Jan; 169(1):48-55. PubMed ID: 25383770
[TBL] [Abstract][Full Text] [Related]
7. Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA.
Hsu HE; Rydzak CE; Cotich KL; Wang B; Sax PE; Losina E; Freedberg KA; Goldie SJ; Lu Z; Walensky RP;
HIV Med; 2011 Feb; 12(2):97-108. PubMed ID: 20561082
[TBL] [Abstract][Full Text] [Related]
8. Birth defects following exposure to efavirenz-based antiretroviral therapy during pregnancy: a study at a regional South African hospital.
Bera E; McCausland K; Nonkwelo R; Mgudlwa B; Chacko S; Majeke B
AIDS; 2010 Jan; 24(2):283-9. PubMed ID: 19864931
[TBL] [Abstract][Full Text] [Related]
9. Pregnancy outcomes following exposure to efavirenz based antiretroviral therapy in indian women.
Mishra RK; Chakravarty R; Siddique N; Pandey KR
Indian J Pharmacol; 2020; 52(6):467-471. PubMed ID: 33666186
[TBL] [Abstract][Full Text] [Related]
10. Birth Defects After Exposure to Efavirenz-Based Antiretroviral Therapy at Conception/First Trimester of Pregnancy: A Multicohort Analysis.
Martinez de Tejada B; Gayet-Ageron A; Winterfeld U; Thorne C; Favarato G;
J Acquir Immune Defic Syndr; 2019 Mar; 80(3):316-324. PubMed ID: 30570524
[TBL] [Abstract][Full Text] [Related]
11. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
João EC; Morrison RL; Shapiro DE; Chakhtoura N; Gouvèa MIS; de Lourdes B Teixeira M; Fuller TL; Mmbaga BT; Ngocho JS; Njau BN; Violari A; Mathiba R; Essack Z; Pilotto JHS; Moreira LF; Rolon MJ; Cahn P; Prommas S; Cressey TR; Chokephaibulkit K; Werarak P; Laimon L; Hennessy R; Frenkel LM; Anthony P; Best BM; Siberry GK; Mirochnick M
Lancet HIV; 2020 May; 7(5):e322-e331. PubMed ID: 32386720
[TBL] [Abstract][Full Text] [Related]
12. Commentary: Antiretroviral treatment for pregnant and breastfeeding women--the shifting paradigm.
Tsague L; Abrams EJ
AIDS; 2014 Mar; 28 Suppl 2():S119-21. PubMed ID: 24849470
[No Abstract] [Full Text] [Related]
13. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.
Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Gaolethe T; Petlo C; Lockman S; Holmes LB; Makhema J; Shapiro RL
Lancet Glob Health; 2018 Jul; 6(7):e804-e810. PubMed ID: 29880310
[TBL] [Abstract][Full Text] [Related]
14. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
[TBL] [Abstract][Full Text] [Related]
15. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
[TBL] [Abstract][Full Text] [Related]
16. Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study.
Williams PL; Yildirim C; Chadwick EG; Van Dyke RB; Smith R; Correia KF; DiPerna A; Seage GR; Hazra R; Crowell CS;
Lancet HIV; 2020 Jan; 7(1):e49-e58. PubMed ID: 31740351
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
Kanters S; Vitoria M; Doherty M; Socias ME; Ford N; Forrest JI; Popoff E; Bansback N; Nsanzimana S; Thorlund K; Mills EJ
Lancet HIV; 2016 Nov; 3(11):e510-e520. PubMed ID: 27658869
[TBL] [Abstract][Full Text] [Related]
18. Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana.
Bussmann H; Wester CW; Wester CN; Lekoko B; Okezie O; Thomas AM; DeGruttola SM; Makhema J; Essex M; Marlink RG
J Acquir Immune Defic Syndr; 2007 Jul; 45(3):269-73. PubMed ID: 17450102
[TBL] [Abstract][Full Text] [Related]
19. Prenatal exposure to zidovudine and risk for ventricular septal defects and congenital heart defects: data from the Antiretroviral Pregnancy Registry.
Vannappagari V; Albano JD; Koram N; Tilson H; Scheuerle AE; Napier MD
Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():6-10. PubMed ID: 26687320
[TBL] [Abstract][Full Text] [Related]
20. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Volmink J; Siegfried NL; van der Merwe L; Brocklehurst P
Cochrane Database Syst Rev; 2007 Jan; (1):CD003510. PubMed ID: 17253490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
